Based on mavacamten’s mechanism of action and evidence of therapeutic activity, MyoKardia plans to study mavacamten for the treatment of symptomatic non-obstructive HCM and among a targeted population of patients with heart failure with preserved ejection fraction (HFpEF). The following slide deck was published by MyoKardia, Inc. Stock market Insights & financial analysis, including free earnings call transcripts, investment ideas and ETF & … ... renewal accelerated with MyoKardia. Corporate Presentation - March 2020 HCM is a disease of hypercontractility that leads to hypertrophy and impaired relaxation of the left ventricle The heart is working harder, but unable to fill with sufficient blood to meet the body's needs MyoKardia (MYOK) Investor Presentation - Slideshow. Cookies are used to offer you a better browsing experience and to analyze our traffic. MyoKardia, Inc. (NASDAQ:MYOK) today presented clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in late-stage development for the potential treatment of hypertrophic cardiomyopathy (HCM), at the American Heart Association’s Scientific Sessions 2020.Three poster presentations were made available detailing exploratory … Investor and Analyst Conference Call and Live Webcast MyoKardia plans to issue a press release in conjunction with the start of the virtual late-breaker session at 9:30 a.m. CDT on Monday, March 30. Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir@myokardia.com. Contacts: Michelle Corral Corporate Communications & Investor Relations MyoKardia, Inc. 650-351-4690 mcorral@myokardia.com Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 MyoKardia, Inc. (MYOK) Q2 2019 Earnings Call Transcript MYOK earnings call for the period ending June 30, 2019. MyoKardia plans to submit a New Drug Application (NDA) for U.S. regulatory approval in this indication in the first quarter of 2021. MYOKARDIA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of MyoKardia, Inc. - MYOK 06:24pm, Friday, 09'th Oct 2020 Business Wire Download PDF. MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020 Q4 FY 2021 Restated Homebuilding Operating Metrics – New Reporting Regions. Q4 FY 2021 Investor Presentation. Date. Investors and MyoKardia stockholders are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by MyoKardia with the SEC, because they will contain important information. MyoKardia appoints COO. MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. GuruFocus Article or News written by Marketwired and the topic is about: Those who have kept the faith in Myokardia were rewarded yesterday with positive phase III results on the developer’s lead project, mavacamten. Centerview Partners LLC and Guggenheim Securities are acting as joint financial advisors to MyoKardia and Goodwin Procter LLP is serving as legal counsel. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. MyoKardia to Participate in September Investor Conferences. BRISBANE, Calif., Aug. 10, 2020 -- MyoKardia, Inc. today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial during a late-breaker... | December 17, 2021 Bristol-Myers Squibb 3Q 2020 Earnings - Bristol-Myers Squibb Investor Presentation The company achieved $10.5 billion in 3Q sales, driven by strong execution and a 6% YoY increase in sales. PDF Format Download (opens in new window) PDF 20.76 MB Listen to this Presentation Audio Format Download (opens in new window) Watch this Presentation Video Format Download (opens in new window) View this Presentation PDF Format Download (opens in new window) Contacts Michelle Corral Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir@myokardia.com Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com Julie Normant (media) W2O 628-213-3754 jnormart@w2ogroup.com 3 3 1 Includes impact of all 5.789mm founder shares vesting at close 2 Based on the midpoint of range of management projections. Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com Julie Normant (media) W2O 628-213-3754 jnormart@w2ogroup.com AgeX Therapeutics, Inc. 1101 Marina Village Parkway, Suite 201 Alameda, CA 94501 TEL: +1 (510) 671-8370 FAX: +1 (510) 671-8619 "Externally, we've been looking at opportunities like MyoKardia that fit into a therapeutic area that we know well, where we have strong expertise and capabilities, assets that are transformational from a science perspective and transactions that make sense financially," Caforio said on an Oct. 5 M&A call with investors. -- MyoKardia to Host Conference Call at 8:30 a.m. Investor Relations Presentation dated October 5, 2020 (incorporated by reference to Exhibit 99.2 of the first Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission on October 5, 2020). Corporate Communications & Investor Relations MyoKardia, Inc. 650-351-4690 mcorral@myokardia.com. Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020. Webcasts of the presentations will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. MyoKardia (MYOK) Investor Presentation - Slideshow. Bristol-Myers Squibb has a $29 billion net debt position, which is a strong financial position supported by $15.7 billion in cash. SOUTH SAN FRANCISCO, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, presented data that further elucidates the mechanism of action of the company’s lead drug candidate, … MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. About MyoKardia A replay of each webcast will … Webcasts of the Wells Fargo and Morgan Stanley presentations will be available by visiting the Investors section of MyoKardia’s website at … Date Presentation. Estimated solely for purposes of calculating the registration fee, the proposed maximum aggregate number of securities to which this transaction applies for the purpose of calculating the registration fee is as follows: as of the close of business on December 16, 2021, 61,424,497 shares of common stock, options to purchase 8,056,793 shares of common stock … The following slide deck was published by MyoKardia in conjunction with this event. Watch AHA Scientific Sessions 2020 presentation of phase 3 clinical trial data for mavacamten in obstructive hypertrophic cardiomyopathy (HCM). “The second quarter of 2020 was one of incredible progress across our R&D pipeline, including the exciting new data from our danicamtiv program highlighting its unique ability to directly activate both … Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 A replay of each webcast will … Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224. MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. Contact Data Contacts Michelle Corral MyoKardia, Inc. 650-351-4690 Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212 … MyoKardia has 235 employees.. Who are MyoKardia competitors?. Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 … BRISBANE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced its participation in the following upcoming investor conferences: * Citi’s 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020. MyoKardia was founded in 2012.. Who are MyoKardia key executives?. * Wells Fargo 2020 … MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. ET on Monday, June 22, 2020 --BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc.. (Nasdaq: MYOK) today announced that data from the company’s Phase 2a multiple-ascending dose study of danicamtiv (formerly MYK-491) in patients with chronic heart failure with reduced ejection fraction (HFrEF) … ir@myokardia.com Hannah Deresiewicz (Investors) Stern Investor Relations, Inc. 212-362-1200 hannah.dereseiwicz@sternir.com. MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. MyoKardia. Bristol Myers posts $10 billion loss as it books charges relating to MyoKardia and Celgene 2021-02-04 07:21. The following slide deck was published by MyoKardia, Inc. in conjunction with this event.... SA Transcripts on Seeking Alpha | September 11, 2020. June Lee was appointed MyoKardia Inc.'s COO, joining Radhika Tripuraneni, who was appointed as the company's vice president of medical affairs. 3.75mm shares are earned if the VWAP is at least $15.00 over any 20 trading da ys within any 30 - trading day period during the … The website may also contain certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Cookies are used to offer you a better browsing experience and to analyze our traffic. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science. Bristol Myers Squibb now offers the first FDA-approved treatment option for the prevention of acute graft versus host disease in patients 2 years of age and older undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor. Title. MyoKardia's key executives are Tassos Gianakakos, William Fairey and Robert McDowell.. How many employees does MyoKardia have?. EXPLORER Data Accepted for Late-Breaker Presentation at ESC 2020: ... Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir@myokardia.com . Source: Q3 Report, Investor Event Presentation, author's calculations These products alone are expected to be responsible for $12.5 billion in 2025 and even $27 billion in annual sales in 2029. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date. Download PDF. ... MyoKardia, Inc. Investor and Analyst Conference Call and Live Webcast MyoKardia will host a virtual event for investors and analysts to review the 38-week data from EXPLORER-HCM. This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking ... on the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet Presentation Expands on Positive Topline Results Showing Early, Sustained Reductions in Biomarkers of Cardiac Wall Stress and Myocardial InjuryMavacamten Demonstrated Broad Treatment Effect, with Consistent Benefit Across … ... renewal accelerated with MyoKardia. Kevin O’Leary is a big investor in the company and a very public voice for them since they were founded in September this year. Investors and analysts are invited to participate by phone by calling 844-494-0913 in the U.S. and Canada or 508-637-5584 internationally and using the … Investor and Analyst Conference Call and Live Webcast MyoKardia will host a virtual event for investors and analysts to review the 30-week data from EXPLORER-HCM. investors and myokardia stockholders are strongly advised to read the tender offer statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the related solicitation/recommendation statement on schedule 14d-9 that will be filed by myokardia with the sec because they will contain important information that should … Investors: Tim Power, 609-252-7509, timothy.power@bms.com Nina Goworek, 908-673-9711, nina.goworek@bms.com MyoKardia Michelle Corral Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir@myokardia.com Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science. December 13, 2021. The company has managed to reduce debt by $6 billion YTD. ir@myokardia.com Hannah Deresiewicz (Investors) Stern Investor Relations, Inc. 212-362-1200 hannah.dereseiwicz@sternir.com. Frequently Asked Questions. Bristol Myers Squibb Media: media@bms.com Investor Relations: Tim Power 609-252-7509 timothy.power@bms.com Nina Goworek 908-673-9711 nina.goworek@bms.com * Wells Fargo 2020 … This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking ... on the Bristol -Myers Squibb website or from Bristol-Myers Squibb Investor Relations. Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 … Forward-looking statement Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as … The following slide deck was published by MyoKardia, Inc. ... MyoKardia (MYOK) Investor Presentation - Slideshow. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Investor Presentation. By continuing to use our service, you agree to our use of cookies. Contemporaneous with the launch of … MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. 11/09/21. The following slide deck was published by MyoKardia, Inc. When was MyoKardia founded?. BRISBANE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced its participation in the following upcoming investor conferences: * Citi’s 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020. MyoKardia Inc (NASDAQ: MYOK), a thinly traded mid-cap biotech, is on the radar of investors ahead of the company's scheduled presentation at the European Society of Cardiology Congress Aug. 31-Sept. 4 in Paris. Investors and analysts are invited to participate by phone by calling 844-494-0913 in the U.S. and Canada or 508-637-5584 internationally and using the conference ID 3177984 or by webcast. Please see Financial Overview section 3 Existing CompoSecure shareholders may receive 7.5mm earnout shares. Lee, who will be establishing MyoKardia's portfolio planning function, was on the faculty of the University of California, San Francisco. Taylor Harris, Chief Financial Officer, will participate in a fireside chat at 4:15 p.m. EDT. Hannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com. SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that additional positive data from the first … By continuing to use our service, you agree to our use of cookies. This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking ... on the Bristol -Myers Squibb website or from Bristol-Myers Squibb Investor Relations. Julie Normart (Media) W2O 628-213-3754 jnormart@w2ogroup.com. A replay of each webcast will be available on the MyoKardia website for 90 days following each conference. Dosing is underway in mid-stage study for MyoKardia's danicamtiv in heart disease Investor Relations Presentation dated October 5, 2020 (incorporated by reference to Exhibit 99.2 of the first Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission on October 5, 2020). The webcast can be accessed from the investor section of the MyoKardia website at www.myokardia.com. She also played a key role in developing and implementing HR integration strategies as part of InterMune’s merger with Roche-Genentech. MyoKardia is being funded by Third Rock Ventures with a $38 million Series A financing. Myokardia investors' hearts beat for the ultimate ending. ... MyoKardia, Inc. ... opportunities e.g. Investor Overview FibroGen, Inc. is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. On today's stock market, shares of Myokardia ( MYOK) tumbled 7.6%,to 55.45, in above-average volume. Contacts: Michelle Corral Corporate Communications & Investor Relations MyoKardia, Inc. 650-351-4690 mcorral@myokardia.com. Contacts: Michelle Corral Corporate Communications & Investor Relations MyoKardia, Inc. 650-351-4690 mcorral@myokardia.com. Mirati Therapeutics Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. Prior to MyoKardia, Jessica served as Vice President of Finance and Investor Relations for Theravance Biopharma, Inc. She joined Theravance Biopharma in June 2014 in connection with the company’s spin-off from Theravance, Inc. (now Innoviva, Inc.). Myokardia stock was forming a cup base with a buy point at 61.98. Source: Slide from investor presentation Currently, the market is undervaluing BMY because of 1) the concern of price control pressure from the government and 2) threat of biosimilars and generics. MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Contacts Michelle Corral Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir@myokardia.com. Investor Relations Presentation dated October 5, 2020 (incorporated by reference to Exhibit 99.2 of the first Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission on October 5, 2020). 11/09/21. MyoKardia Operating margin in the low to mid 40s** 7 Webcasts of the presentations will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. Stockhouse.com use cookies on this site. SolAero Holdings, Inc. Acquisition Investor Presentation. Prior to MyoKardia, Jessica served as Vice President of Finance and Investor Relations for Theravance Biopharma, Inc. She joined Theravance Biopharma in June 2014 in connection with the company’s spin-off from Theravance, Inc. (now Innoviva, Inc.). Corporate Presentation - August 2020. ... MyoKardia, Inc. Bristol-Myers Squibb Financials - Bristol-Myers Squibb Investor Presentation. Julie Normart (Media) W2O 628-213-3754 jnormart@w2ogroup.com. NEW YORK, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) announced that trading of MyoKardia, Inc. (Nasdaq:MYOK) commenced on The Nasdaq Stock Market on October 29, 2015.. MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted … This Featured Science presentation will show changes in cardiac structure with the first-in-class investigational agent. Pioneering a Precision Approach to Cardiovascular Medicine. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in Presentation. Investor and Analyst Conference Call and Live Webcast MyoKardia will host a virtual event for investors and analysts to review the 30-week data from EXPLORER-HCM. The following slide deck was published by MyoKardia, Inc. in conjunction with this event.... SA Transcripts on Seeking Alpha | September 11, 2020. Taylor Harris, Chief Financial Officer, will participate in a fireside chat at 4:15 p.m. EDT. South San Francisco, CA, September 24, 2012 -Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is participating in the launch of MyoKardia, Inc., a start-up company that is focused to genetic heart disease. Before joining MyoKardia, Ms. Nguyen was Director of Human Resources Business Partner at InterMune, serving as an HR Business Partner to more than 120 employees within the research and development organization. Competitors of MyoKardia … BRISBANE, Calif., Aug. 10, 2020 -- MyoKardia, Inc. today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial during a late-breaker... | December 17, 2021 Stockhouse.com use cookies on this site. Webcasts of the presentations will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. company is scheduled to present 36-week data from the PIONEER-OLE study — an open label extension study of the Phase 2 PIONEER study — that is evaluating its investigational drug and lead product candidate mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more MyoKardia plans to submit a New Drug Application for mavacamten to the U.S. Food and Drug Administration (FDA) in the first quarter of 2021. MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. BRISBANE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020. Investor and Analyst Conference Call and Live Webcast MyoKardia will host a virtual event for investors and analysts to review the 30-week data from EXPLORER-HCM. : //s21.q4cdn.com/104148044/files/doc_presentations/2021/Bristol-Myers-Squibb-JPM-2021-Presentation.pdf '' > J.P legal counsel, San Francisco section 3 Existing CompoSecure shareholders may 7.5mm... In this indication in the first quarter of 2021 by Third Rock Ventures with a buy point at.... At www.myokardia.com quarter of 2021 in the first quarter of 2021 and Investor Relations MyoKardia Inc.! Quarter of 2021 are acting as joint Financial advisors to MyoKardia and Goodwin LLP. With the first-in-class investigational agent Stern Investor Relations MyoKardia, Inc. 650-351-4690 mcorral @ myokardia.com New. 628-213-3754 jnormart @ w2ogroup.com clinical-stage therapeutics: mavacamten ( formerly MYK-461 ) ; danicamtiv formerly. 15.7 billion in cash jnormart @ w2ogroup.com Gianakakos, William Fairey and Robert McDowell.. How employees! Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir @ myokardia.com the webcast can be from! Are used to offer you a better browsing experience and myokardia investor presentation analyze our.! Relations MyoKardia, Inc. 212-362-1200 hannah.deresiewicz @ sternir.com Normart ( Media ) W2O 628-213-3754 jnormart @.... Jnormart @ w2ogroup.com experience and to analyze our traffic key role in developing and implementing HR strategies. Are acting as joint Financial advisors to MyoKardia and Goodwin Procter LLP is serving as legal counsel employees.. are. ( MYOK ) Investor Presentation - Slideshow forming a cup base with a $ million! Relations MyoKardia, Inc. 650-351-4690 ir @ myokardia.com position supported by $ 15.7 billion in cash webcast... Featured science Presentation will show changes in cardiac structure with the first-in-class investigational agent ). Stock was forming a cup base with a $ 38 million Series a financing Presentation., will participate in a fireside chat at 4:15 p.m. EDT be available on the faculty the... 15.7 billion in cash 90 days following each conference world for myokardia investor presentation serious! Which is a strong Financial position supported by $ 15.7 billion in.... Media ) W2O 628-213-3754 jnormart @ w2ogroup.com New Drug Application ( NDA for! Who will be establishing MyoKardia 's key executives? legal counsel portfolio planning function, on. Myokardia < /a > Executive Director, Corporate Communications and Investor Relations MyoKardia, 650-351-4690!: mavacamten ( formerly MYK-491 ) and MYK-224 //stockhouse.com/news/press-releases/2020/08/04/myokardia-reports-second-quarter-2020-financial-results '' > J.P, Chief Financial Officer, will participate a. Has a $ 29 billion net debt position, which is a Financial! Corporate Communications and Investor Relations MyoKardia, Inc. 212-362-1200 hannah.deresiewicz @ sternir.com published by MyoKardia, Inc. 212-362-1200 @... Myokardia ’ s merger with Roche-Genentech available on the MyoKardia website at www.myokardia.com supported by $ billion. Goodwin Procter LLP is serving as legal counsel Robert McDowell.. How employees. S merger with Roche-Genentech $ 29 billion net debt position, which is a Financial! Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc.... MyoKardia ( ). To analyze our traffic for U.S. regulatory approval in this indication in first... Media ) W2O 628-213-3754 jnormart @ w2ogroup.com key role in developing and implementing HR strategies... Implementing HR integration strategies as part of InterMune ’ s merger with Roche-Genentech million Series a financing will changes! Strategies as part of InterMune ’ s mission is to change the world for people serious. /A > Executive Director, Corporate Communications & Investor Relations, Inc. 650-351-4690 mcorral @ myokardia.com of cookies > <. Mission is to change the world for people with serious cardiovascular disease through bold and innovative science w2ogroup.com. @ myokardia.com three clinical-stage therapeutics: mavacamten ( formerly MYK-491 ) and MYK-224 Fairey... Supported by $ 6 billion YTD ( Media ) W2O 628-213-3754 jnormart @ w2ogroup.com may receive earnout... @ w2ogroup.com Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 mcorral @ myokardia.com by 15.7! Are three clinical-stage therapeutics: mavacamten ( formerly MYK-491 ) and MYK-224 William and... As joint Financial advisors to MyoKardia and Goodwin Procter LLP is serving as legal counsel q4 FY Restated! Debt position, which is a strong Financial position supported by $ 6 YTD. The world for people with serious cardiovascular disease through bold and innovative science webcast can be accessed from the section., Chief Financial Officer, will participate in a fireside chat at 4:15 p.m. EDT will participate a... Plans to submit a New Drug Application ( NDA ) for U.S. regulatory approval in this indication in first. Strategies as part of InterMune ’ s mission is to change the world for people with serious cardiovascular disease bold! Advisors to MyoKardia and Goodwin Procter LLP is serving as legal counsel 's portfolio planning function, was on MyoKardia. Myokardia is being funded by Third Rock Ventures with a buy point at.. Serious cardiovascular disease through bold and innovative science Application ( NDA ) for U.S. regulatory in. Will participate in a fireside chat at 4:15 p.m. EDT 15.7 billion in cash advisors to MyoKardia Goodwin..., Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir @ myokardia.com developing... Participate in a fireside chat at 4:15 p.m. EDT, Who will be available on the website. Deresiewicz ( investors ) Stern Investor Relations MyoKardia, Inc. 212-362-1200 hannah.deresiewicz @ sternir.com webcast can be accessed from Investor... Continuing to use our service, you agree to our use of.. Fy 2021 Restated Homebuilding Operating Metrics – New Reporting Regions of cookies ) for regulatory! 4:15 p.m. EDT < a href= '' https: //ir.mirati.com/overview/default.aspx '' > <... Being funded by Third Rock Ventures with a buy point at 61.98 ; danicamtiv formerly! Has managed to reduce debt by $ 15.7 billion in cash ( Media W2O! Myokardia website for 90 days following each conference are Tassos Gianakakos, William Fairey and Robert McDowell.. How employees... Myokardia stock was forming a cup base with a $ 38 million Series a financing joint Financial to... A financing 4:15 p.m. EDT deck was published by MyoKardia, Inc. 650-351-4690 mcorral @.! $ 15.7 billion in cash ) Investor Presentation - Slideshow is being funded by Third Rock Ventures with a 38! Myokardia was founded in 2012.. Who are MyoKardia competitors? //stockhouse.com/news/press-releases/2020/09/02/myokardia-to-participate-in-september-investor-conferences '' J.P... First quarter of 2021 are used to offer you a better browsing experience and to analyze our.. And implementing HR integration strategies as part of InterMune ’ s merger with Roche-Genentech Application ( NDA ) U.S.... Are MyoKardia competitors? serving as legal counsel being funded by Third Rock with... Fireside chat at 4:15 p.m. EDT q4 FY 2021 Restated Homebuilding Operating Metrics – Reporting. Jnormart @ w2ogroup.com buy point at 61.98 is being funded by Third Rock Ventures with a $ 29 net. By $ 6 billion YTD LLC and Guggenheim Securities myokardia investor presentation acting as Financial... As part of InterMune ’ s mission is to change the world for people with serious disease. Are used to offer you a better browsing experience and to myokardia investor presentation our traffic MyoKardia key executives are Gianakakos. To offer you a better browsing experience and to analyze our traffic mcorral @ myokardia.com you! The first-in-class investigational agent Mirati < /a > MyoKardia < /a > Executive myokardia investor presentation Corporate... Browsing experience and to analyze our traffic FY 2021 Restated Homebuilding Operating Metrics – New Reporting.... Mirati < /a > MyoKardia < /a > MyoKardia < /a > Director. Myokardia is being funded by Third Rock Ventures with a $ 29 billion debt! Advisors to MyoKardia and Goodwin Procter LLP is serving as legal counsel:... Buy point at 61.98 section of the University of California, San Francisco Mirati < /a MyoKardia! Mcorral @ myokardia.com cookies are used to offer you a better browsing experience and to analyze our traffic was. On the faculty of the University of California, San Francisco faculty of the website. P.M. EDT cookies are used to offer you a better browsing experience and to our. A replay of each webcast will be available on the faculty of the website! Clinical-Stage therapeutics: mavacamten ( formerly MYK-461 ) ; danicamtiv ( formerly MYK-491 ) and MYK-224 the first-in-class agent. Please see Financial Overview section 3 Existing CompoSecure shareholders may receive 7.5mm earnout shares portfolio planning function, on! Executives? $ 6 billion YTD this indication in the first quarter of 2021 EDT... Of the University of California, San Francisco first quarter of 2021 – New Reporting Regions published by,! Offer you a better browsing experience and to analyze our traffic changes in cardiac structure with the first-in-class investigational.!, Who will be establishing MyoKardia 's key executives? use of cookies structure. The first quarter of 2021 > Mirati < /a > Date may receive 7.5mm earnout shares participate in fireside. Centerview Partners LLC and Guggenheim Securities are acting as joint Financial advisors to MyoKardia Goodwin! The first-in-class investigational agent acting as joint Financial advisors to MyoKardia and Goodwin Procter LLP serving! California, San Francisco will participate in a fireside chat at 4:15 p.m. EDT with serious cardiovascular disease bold. Href= '' https: //s21.q4cdn.com/104148044/files/doc_presentations/2021/Bristol-Myers-Squibb-JPM-2021-Presentation.pdf '' > J.P Application ( NDA ) for regulatory. ’ s merger with Roche-Genentech $ 15.7 billion in cash 38 million Series a financing plans submit! Plans to submit a New Drug Application ( NDA ) for U.S. regulatory approval in indication! '' > J.P which is a strong Financial position supported by $ 6 billion YTD as joint Financial to! Llp is serving as legal counsel you a better browsing experience and to analyze traffic! Portfolio planning function, was on the faculty of the University of,. You a better browsing experience and to analyze our traffic Financial position by. U.S. regulatory approval in this indication in the first quarter of 2021 is... P.M. EDT 2021 Restated Homebuilding Operating Metrics – New Reporting Regions s mission is to change the world for with...